Urinary C-type natriuretic peptide: An emerging biomarker for heart failure and renal remodeling

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

The public health and economic burden of heart failure (HF) is staggering and the need for relevant pathophysiologic and clinical biomarkers to advance the field and improve HF therapy remains high. Renal dysfunction is common among HF patients and is associated with increased HF hospitalization and mortality. It is widely recognized that mechanisms contributing to HF pathogenesis include a complex bidirectional interaction between the kidney and heart, encompassed by the term cardiorenal syndrome (CRS). Among a new wave of urinary biomarkers germane to CRS, C-type natriuretic peptide (CNP) has emerged as an innovative biomarker of renal structural and functional impairment in HF and chronic renal disease states. CNP is a hormone, synthesized in the kidney, and is an important regulator of cell proliferation and organ fibrosis. Hypoxia, cytokines and fibrotic growth factors, which are inherent to both cardiac and renal remodeling processes, are among the recognized stimuli for CNP production and release. In this review we aim to highlight current knowledge regarding the biology and pathophysiological correlates of urinary CNP, and its potential clinical utility as a diagnostic and prognostic biomarker in HF and renal disease states.

Original languageEnglish (US)
Pages (from-to)108-113
Number of pages6
JournalClinica Chimica Acta
Volume443
DOIs
StatePublished - Mar 1 2015

Keywords

  • Biomarker
  • C-type natriuretic peptide
  • Cardiorenal syndrome
  • Heart failure
  • Renal remodeling

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Biochemistry, medical

Fingerprint Dive into the research topics of 'Urinary C-type natriuretic peptide: An emerging biomarker for heart failure and renal remodeling'. Together they form a unique fingerprint.

  • Cite this